Civox-200 mg injection should be administered by slow intravenous infusion over a period of 60 minutes. It should not be given by rapid intravenous bolus injection. Ensure appropriate dilution if necessary and check for particulate matter before administration.

Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, essential enzymes involved in DNA replication, transcription, repair, and recombination. This leads to bacterial cell death.

• •Hypersensitivity to Ciprofloxacin, any other fluoroquinolone, or any component of the formulation.
• •Concomitant administration with Tizanidine due to the risk of increased Tizanidine plasma concentrations, which can lead to clinically significant hypotension and sedation.

Store below 25°C. Protect from light. Do not freeze. Keep out of reach of children.

In the event of an acute overdose, reversible renal toxicity has been reported in some cases. Management involves symptomatic and supportive care. Hemodialysis or peritoneal dialysis removes only a small amount of Ciprofloxacin from the body.

Pregnancy Category C. Ciprofloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Ciprofloxacin is excreted into human breast milk. Due to the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.